HISTOPATHOLOGIC FEATURES OF CENTRAL GIANT CELL GRANULOMA TREATED BY DENOSUMAB

Central giant cell granulomas (CGCGs) are benign lesions of the jaws. Surgical management may cause significant morbidity, and noninvasive therapies such as intralesional corticoid, calcitonin, and, more recently, denosumab have been used as an option. The study aimed to describe histopathologic characteristics of CGCGs treated by denosumab. A 39-year-old man was referred to treat a CGCG. The imaginological examinations showed an extensive osteolytic lesion affecting the left maxilla. Tumor board evaluation proposed systemic therapy with denosumab. Four doses of denosumab (120 mg) were administered during the first month followed by 2 monthly doses (Thomas, 2010). After 3 months, there was facial edema, and the patient refused follow-up. Surgical treatment was performed, and the histopathologic examination showed a granulation tissue in a central region and a formation of mature bone trabeculae in the periphery. Typical areas of CGCG were not observed. This report shows that denosumab inhibits the giant cells of CGCG.